Every material Form 8-K enVVeno Medical Corp has filed with the SEC since February 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
enVVeno Medical Corporation issued an investor presentation on July 14, 2026, which it may use with investors, analysts and others. The filing states the presentation is attached as Exhibit 99.1 but does not summarize its contents, so the filing itself reports no new financial results, guidance or deal terms.
Investor presentation issued July 14, 2026, attached as Exhibit 99.1
Company may use the presentation at investor, analyst and other meetings, in whole or in part
Filing contains no financial figures, guidance or transaction terms in its text
enVVeno Medical said the FDA approved its Investigational Device Exemption application, allowing a pivotal U.S. study of its enVVe non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency. The company said it had approximately $25 million in cash and investments as of March 31, 2026, expected to fund operations into the third quarter of 2027.
FDA approved the IDE application for the TAVVE pivotal study, announced April 29, 2026.
First stage will enroll 10 patients, with 30-day safety results submitted to the FDA; second stage will enroll 220 patients (165 receiving the enVVe valve, 55 in a control arm).
Study will enroll at up to 40 U.S. clinical sites; first stage is expected to commence later this year.
Cash and investments were approximately $25 million as of March 31, 2026, expected to fund operations into Q3 2027.
enVVeno Medical said Nasdaq notified it that the company regained compliance with the $1.00 minimum bid price rule and that the matter is closed. The company also reported cash and investments of approximately $28 million as of December 31, 2025. The filing does not include revenue, net loss, or guidance, and the company says it expects to share more details on its 2026 strategic plans in the coming weeks.
Nasdaq confirmed the closing bid price was at or above $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026.
Cash and investments were approximately $28 million as of December 31, 2025.
The company expects to share additional details on its 2026 strategic plans in the coming weeks.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every enVVeno Medical Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →